GOT2 and nonpapillary renal cell carcinoma: Another study indicated that GOT2 expression in ccRCC patients is significantly correlated with methylation levels at multiple CpG sites, suggesting that epigenetic silencing of GOT2 may be a critical factor driving tumorigenesis (52).